BNET Industries
Market Cap:$1.2B
Last Fiscal Year Sales:$178.7M
- Public
- US
Dow Jones Description
We are a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. Our strategy is to:
Number of Employees 280
Contact Information
1700 Perimeter Dr
Morrisville, North Carolina 27560-8404
(919) 862-1000
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
3rd-quarter profits rise for Talecris
-
Revenue at Salix starts to rebound
-
Salix Pharma in $5M licensing deal with Lupin
-
Lupin Grants Salix Pharma SLXP Exclusive US Rights for Bioadhesive Drug Delivery Technology with Rifaximin
-
Wells Fargo Maintains a 'Market Perform' on Salix Pharmaceuticals SLXP; Raises Valuation Range
-
Lupin Licenses US Rights for Proprietary Bioadhesive Technology for Rifaximin to Salix Pharmaceuticals
-
JMP Securities Initiates Coverage on Salix Pharmaceuticals SLXP with a Market Outperform
-
Stocks in the Spotlight Monday
-
Piper Jaffray Maintains an 'Overweight' Rating on Salix Pharmaceuticals SLXP; Raises Price Target
-
Wilmington Pharmaceuticals gets go-ahead on its first melt-in-your-mouth medicine
-
Salix can sell its new drug
-
Salix wins FDA approval for stomach and heartburn drug
-
Salix Pharmaceuticals Q2 net loss doubles
-
Napo Pharmaceuticals Completes Dose Selection Phase of ADVENT Trial
-
Salix plans to add 64 salespeople
-
Analysts' Upgrades, Downgrades: KB Home
News & Analysis
Filter by
salix pharmaceuticals ltd. - All News and Analysis
Salix Pharmaceuticals Ltd Q3 2009 Earnings Call Transcript
Seeking Alpha
- 2009-11-09
Question-and-Answer SessionOperator Thank you. The question-and-answer session will be conducted electronically. Operator Instructions. We'll go first to Michael Tong with Wells Fargo Securities. Michael Tong - Wells Fargo Securities Adam, is there anything strange going on with the XIFAXAN revenue for the quarter, seems quite a bit high? Secondly,...
Salix: Approval of Rifaximin Would Help Drive Long-Term Growth
Seeking Alpha
- 2009-09-29
Zacks.com submits: Salix Pharmaceuticals SLXP Analyst Report is working on gaining approval from the U.S. Food and Drug Administration (FDA) for new indications of rifaximin, which should help in driving long-term growth. Rifaximin is currently marketed for the treatment of patients, aged 12 years or more, with travelers...
Salix Pharma Continues to Rise in Anticipation of FDA Decision
Seeking Alpha
- 2009-09-06
Shares of Salix Pharmaceuticals (NASDAQ:SLXP) have been rising in anticipation of their upcoming FDA decision, which is due this coming week. Shares for the company rose as much as 34% since July and on September 11, the FDA is scheduled to decide whether or not to approve the company's Metozolv...
Salix Pharmaceuticals, Ltd. Q4 2008 Earnings Call Transcript
Seeking Alpha
- 2009-03-10
Question-and-Answer Session Operator Operator instructions. We will go first to Michael Tong with Wachovia Capital. Michael Tong – Wachovia Capital Adam, just a couple of P&L questions. I noticed the gross margin in the fourth quarter was a little bit below where the company was trending...
Salix Pharmaceuticals, Ltd. Q3 2008 Earnings Call Transcript
Seeking Alpha
- 2008-11-21
Question-and-Answer SessionOperator Thank you. At this time, we invite all listeners to ask questions. Operator instructions We will go first to Bert Hazlett with BMO Capital Markets. Bert Hazlett – BMO Capital Markets Thanks. Thanks for taking the question. Well, congratulations on the approval, first of all – of...
Salix Pharmaceuticals Ltd. Q2 2008 Earnings Call Transcript
Seeking Alpha
- 2008-08-04
Question-and-Answer SessionOperator Operator Instructions. We'll go first to Scott Hirsch with Credit Suisse. Scott Hirsch - Credit Suisse Yeah, hi, guys, a few questions for you. First of all, can you give us an update on the AG trial and any status going on with that? Carolyn Logan We...
Salix Pharmaceuticals Ltd. Q1 2008 Earnings Call Transcript
Seeking Alpha
- 2008-05-06
Question-and-Answer SessionOperator And, thank you. Operator Instructions. We will go to Michael Tong with Wachovia Capital. Michael Tong Hi good afternoon Carolyn and Adam. I have just a couple of quick questions. In your revenue guidance for the second quarter, do you incorporate a potentially initial stocking for Balsalazide...
Salix Pharmaceuticals Ltd. Q4 2007 Earnings Call Transcript
Seeking Alpha
- 2008-03-03
Question-and-Answer Session Operator Operator Instructions. Our first question today will come from [Scott Hirsch] with Credit Suisse. Scott Hirsch - Credit Suisse Yeah, hi there. Carolyn Logan All right. Scott Hirsch - Credit Suisse So a few questions for you; one, with respect to the guidance, how much inventory...
Salix Pharmaceuticals Q3 2007 Earnings Call Transcript
Seeking Alpha
- 2007-11-06
Question-and-Answer SessionOperator Operator Instructions And we will take our first question from Michael Tong with Wachovia Securities. Michael Tong - Wachovia Securities Hi. Good afternoon, Carolyn. Carolyn Logan Hi, Michael. Michael Tong - Wachovia Securities Just want to get a little bit better clarity on the, I guess the...
Salix Pharmaceuticals Reports 2Q2005 Results; Total Product Revenue Increases 81% Over 2Q04; Salix Delivers $0.13 EPS
- 2005-08-09
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced financial and operating results for the quarter ended June 30, 2005. Total product revenue was $35.1 million for the second quarter of 2005 compared to $19.4 million for the second quarter of 2004. This represents a year-over-year increase of...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
